Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Tesaro

Evaluate

Thumbnail
January 04, 2019

Big caps provide a safe haven

As the curtain came down on a quarter many in biotech would rather forget, big pharma groups stood out by being the least bad investment option.

Thumbnail
December 03, 2018

Glaxosmithkline’s Tesaro move: start of a new acquisition wave?

The $5bn transaction was surely only made possible by shrinking valuations, but investors in both Glaxo and Tesaro have reasons to be unhappy.

Article image
Vantage logo
November 20, 2018

Patience is a virtue for big pharma buyers

For biotechs nearing regulatory approval the key is to sell before launch. For buyers, playing the waiting game is a better strategy.

Article image
Vantage logo
November 11, 2018

SITC 2018 – The search for immuno-oncology combos continues

Once hotly tipped approaches from Aduro, Tesaro and Merck & Co might yet hold promise, but disappointing early data cuts have burst the bubble of investor…

Article image
Vantage logo
November 08, 2018

Alnylam’s solo launch lives up to its mediocre billing

Article image
Vantage logo
October 24, 2018

Esmo 2018 – Adaptimmune gets the wooden spoon

The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.

Article image
Vantage logo
October 23, 2018

Esmo 2018 – Without overwhelming efficacy the me-too PD-1 chase is futile

Results from Tesaro, Sanofi, Novartis, Merck KGaA and others have come in thick and fast, but can any beat the entrenched leaders?

Article image
Vantage logo
October 21, 2018

Esmo 2018 – Lynparza delivers a huge result in first-line ovarian cancer

A dramatic extension in progression-free survival in Astrazeneca's Solo-1 study raises the prospect of improving cure rates in ovarian cancer, though the impact…

Article image
Vantage logo
October 19, 2018

Esmo 2018 – Encouraging early prostate data fail to lift Clovis

Response rates in BRCA-positive patients hint at Parp inhibitors’ potential in prostate cancer, but Clovis reins in hopes for a different genetic marker.

Article image
Vantage logo
October 17, 2018

Pfizer joins the Parp party

Article image
Vantage logo
August 13, 2018

After Alnylam’s solo maiden launch, here comes the tricky bit

Alnylam has secured its first approval, but history suggests that launch will be far from easy.

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up